Compare Enveric Biosciences Inc (ENVB) vs iShares MSCI South Korea ETF (EWY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs iShares MSCI South Korea ETF — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.69M), while iShares MSCI South Korea ETF trades at $177.95 (market cap $26.77B). The key difference: iShares MSCI South Korea ETF is far larger — about 4001.5× Enveric Biosciences Inc's market cap, and iShares MSCI South Korea ETF is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and iShares MSCI South Korea ETF for 46 Days on average.
| ENVB | EWY | |
|---|---|---|
Market Cap | $6.69M | $26.77B |
Volume | 41,141 | 12,180,040 |
Sector | Health | Broad Market / Factor |
52-Week High | $10.80 | $219.20 |
52-Week Low | $1.27 | $80.72 |
Typical Hold Time | 14 Days | 46 Days |
Enterprise Value | -$1.60M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495, up 1.7% on the day, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The company reported no revenue in 2025 and a net loss of $8.77 million, though it has consistently beaten EPS expectations. Recent news includes a new U.S. patent allowance for its non-hallucinogenic mescaline derivatives and participation in an investment conference.
The outlook remains speculative given the lack of revenue and negative profitability, but analyst consensus is bullish with 75% buy ratings. Key risks include the pre-revenue biotech model and dependence on successful drug development. Upside potential hinges on clinical progress and regulatory milestones for its psychiatric therapeutics pipeline.
EWY (iShares MSCI South Korea ETF) trades at $183.72, down 1.44% amid mixed technical signals with neutral overall momentum. The ETF faces pressure from rising oil prices and global bond yields impacting South Korean semiconductor stocks, though AI-driven demand provides underlying support. Recent volatility around the 7,000 KOSPI level reflects ongoing tension between technology sector strength and macroeconomic headwinds.
Outlook remains cautiously optimistic given South Korea's strong corporate earnings and AI infrastructure growth, but concentrated exposure to Samsung and SK hynix creates sensitivity to memory cycle fluctuations. Key risks include persistent inflation pressures and global semiconductor demand volatility that could challenge near-term performance despite long-term AI tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →
